Pharmaceutical composition, pharmaceutical preparation and application of pharmaceutical composition and pharmaceutical preparation

A technology for pharmaceutical preparations and compositions, which is applied to pharmaceutical compositions, pharmaceutical preparations and their application fields, can solve the problems of strong drug resistance, easy recurrence, and large side effects, achieve good skin penetration, good anti-inflammatory effect, and promote release effect

Inactive Publication Date: 2021-03-16
WUHAN POLYTECHNIC UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, it is mostly believed that its onset is caused by delayed-type allergic reaction mediated by T lymphocytes. Topical application of glucocorticoids on the skin has a certain therapeutic effect, but the side effects are large and drug resistance is strong, and it is easy to relapse or even aggravate the disease. Treatment is difficult and has a great impact on the patient's physical and mental health
There is a significant unmet medical need in this area as there is currently a lack of safe and effective topical treatments for the large mild to moderate allergic dermatitis population
Criborole is a non-hormonal anti-inflammatory drug, its clinical data in the treatment of eczema is very competitive, it may become the first-line therapy for this patient population, and has high clinical application value; however, Criborole In the application, there is a problem that the skin penetration is not very good, which restricts the absorption and efficacy of the drug to a certain extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition, pharmaceutical preparation and application of pharmaceutical composition and pharmaceutical preparation
  • Pharmaceutical composition, pharmaceutical preparation and application of pharmaceutical composition and pharmaceutical preparation
  • Pharmaceutical composition, pharmaceutical preparation and application of pharmaceutical composition and pharmaceutical preparation

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0026] (1) Preparation of the oil phase: Add white petrolatum, paraffin, glyceryl mono- and distearate into the container, heat to 70-80°C to melt under stirring, then add butylated hydroxytoluene, stir to dissolve, and cool to 40-46°C to obtain an oil phase;

[0027] (2) Preparation of the solvent phase: add criborole, Diphenylheptane A, propylene glycol and calcium disodium EDTA into another mixing container, and heat to 40-46° C. under stirring to obtain the solvent phase;

[0028] (3) Emulsification: Add the solvent phase to the oil phase, keep the temperature at 40-46°C for 20 minutes, and cool to 25°C under stirring to obtain a uniform ointment.

[0029] The third aspect of the present invention provides the application of the above pharmaceutical composition in the preparation of anti-inflammatory drugs.

[0030] The fourth aspect of the present invention provides the application of the above-mentioned pharmaceutical composition in the preparation of a medicine for tre...

Embodiment 1

[0035] The present embodiment provides a kind of medicinal ointment, and the specific formula is shown in Table 1, and the specific preparation method is as follows:

[0036] (1) Preparation of the oil phase: Add white petrolatum, paraffin, glyceryl mono- and distearate into the container, heat to 75°C for melting under stirring, then add butylated hydroxytoluene, stir to dissolve, and cool to 45°C ℃, to obtain the oil phase;

[0037] (2) Preparation of the solvent phase: add crisborole, Diphenylheptane A, propylene glycol and calcium disodium EDTA into another mixing vessel, and heat to 45° C. under stirring to obtain the solvent phase;

[0038] (3) Emulsification: Add the solvent phase to the oil phase, keep the temperature at 45°C for 20 minutes, and cool to 25°C under stirring to obtain a uniform ointment.

[0039] Table 1

[0040]

[0041]

Embodiment 2

[0043] This embodiment provides a medicinal ointment, the specific formula is shown in Table 2, and the specific preparation method is the same as that of Embodiment 1.

[0044] Table 2

[0045] components Weight percentW / W Criborole 2％ Diphenylheptane A (Formula Ⅰ) 0.2％ Propylene Glycol 8.8％ Butylated hydroxytoluene 0.1％ Glyceryl monostearate 7％ paraffin 5％ white petrolatum 76.8965％ Calcium disodium EDTA 0.0035％

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition, a pharmaceutical preparation and application of the pharmaceutical composition and the pharmaceutical preparation. The pharmaceutical compositioncomprises Crisaborole and diphenylheptane A. Compared with the Crisaborole, the pharmaceutical composition disclosed by the invention has better transdermal performance and anti-inflammatory effect.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and more specifically relates to a pharmaceutical composition, a pharmaceutical preparation and applications thereof. Background technique [0002] Eczema is an allergic inflammatory skin disease caused by a variety of internal and external factors. It is characterized by symmetrical distribution of skin lesions, polymorphic lesions, severe itching, tendency to exudate, and repeated attacks. At present, it is mostly believed that its onset is caused by delayed-type allergic reaction mediated by T lymphocytes. Topical application of glucocorticoids on the skin has a certain therapeutic effect, but the side effects are large and drug resistance is strong, and it is easy to relapse or even aggravate the disease. Treatment is difficult and has a great impact on the physical and mental health of patients. Currently, there is a significant unmet medical need in this area for the large mild-to-moderat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/69A61K31/12A61K9/06A61P17/00A61P29/00
CPCA61K9/0014A61K9/06A61K31/12A61K31/69A61P17/00A61P29/00A61K2300/00
Inventor 赵玲王薇胡淼淼杨博
Owner WUHAN POLYTECHNIC UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap